Table 4. Baseline Characteristics of Patients in the 20 Studies Included.
| Refs. | No. * | Sex | Age | Blood Eosinophils | FEV1% Predicted | Diagnosis of asthma | PEF |
|---|---|---|---|---|---|---|---|
| (Male, %)* | (Mean SD, y)* | (Mean SD,103/uL)* | (Mean SD, %) * | (mean SD, y)* | (Mean SD, L/min)* | ||
| Leckie 2000[18] | 16 | NM | 29 (6.29) | 0.25 (0.1) | 86.15 (9.58) | NM | NM |
| Flood-Page PT 2003[19] | 11 | 9 (82) | 31 (5.5) | 0.27 (0.18) | 87.0 (6.3) | NM | 433 (37.8) |
| Büttner 2003[20] | 12 | 5 (42) | 44.25 (10.85) | NM | 65.68 (10.48) | 11.75 (9.27) | NM |
| Flood-Page P 2007[21] | 236 | 112 (47) | 36 (29.4) | 0.35 (0.25) | 68.35 (9.2) | NM | 366.6 (90.0) |
| Haldar 2009[22] | 29 | 14 (48) | 48 (7) | 0.32 (0.38)& | 78.1 (20.9) | NM | NM |
| Nair 2009[23] | 9 | 4 (44) | 56.4 (10.9) | 0.68 (0.52) | 66.6 (18.3) | NM | NM |
| Pavord 2012[24] | 461 | 171 (37) | 49.4 (11.2) | 0.24 (1.03)# | 60.0 (16.3) | 19.5 (14.4) | NM |
| Bel 2014[25] | 69 | 25 (36) | 50 (9.7) | 0.25 (1.245)# | 59.6 (17.0) | 17.4 (11.8) | NM |
| Ortega 2014[26] | 385 | 163 (42) | 50.5 (11.5) | 0.285 (1.018)# | 60.3 (17.9) | 20.2 (13.4) | 262 (110) |
| Kips JC 2003[27] | 18 | 12 (67) | 43 (5.9) | 0.26 (0.04) | 53.4 (7.6) | NM | NM |
| Castro 2011[28] | 53 | 19 (36) | 44.9 (13.94) | NM | 66.0 (15.16) | 23.3 (11.38) | NM |
| Castro 2015[29] | Study 1: 245 Study 2: 232 | Study 1: 103 (42) Study 2: 88 (38) | Study 1: 48 (14.1) Study 2: 48 (14.4) | Study 1:0.696 (0.768) Study 2: 0.61 (0.412) | Study 1:63.6 (18.6) Study 2:70.4 (21.0) | Study 1:19.7 (15.2) Study 2:18.2 (14.4) | NM |
| Corren 2016[30] | 398 | 137 (34) | 44.9 | 0.281 (0.264) | 66.8 | 26.2 | NM |
| Bjermer L 2016[31] | 210 | 85 (40) | 43.7 | 0.65 (0.006) | 69.6 | 20.2 | NM |
| Laviolette 2013[32] | cohort 1: 8 cohort 2: 9 | cohort 1: 6 (25) cohort 2: 5 (56) | cohort 1: 38.9 (14.7) cohort 2: 38.9 (13.8) | NM | cohort 1: 70.5 (15.6) cohort 2: 68.7 (11.4) | NM | NM |
| Castro 2014[33] | group 1: 244 group 2: 140 | group 1: 78 (32) group 2: 42 (30) | group 1: 47.2 (12.9) group 2: 50.0 (11.5) | group 1: 0.54 (0.32) group 2: 0.19 (0.12) | group 1: 65.3 (15.3) group 2: 66.8 (15.1) | NM | NM |
| Nowak 2015[34] | 72 | 25 (35) | 36.3 (6.8) | 0.213 (0.393) | 58.1 | NM | NM |
| Park HS 2016[35] | 77 | 29 (38) | 53.4 (11.5) | 0.72 (0.87) | 67.8 (14.4) | NM | NM |
| Bleecker E R 2016[36] | 797 | 270(34) | 48.9(14) | 0.34(0.52) | 56.8(14.4) | 14.9 | NM |
| FitzGerald J M 2016[37] | 866 | 323(37) | 49.5(14) | 0.39(0.42) | 58.4(14.9) | 16.3 | NM |
*Data on all patients who received anti-interleukin 5, and all data are n (%) or mean (SD), unless otherwise stated.
#Geometric mean on loge scale.
&geometric means±log10 SD.
NM: Not Mentioned